This study looks at pleuropulmonary blastoma (PPB), a rare lung cancer that mainly affects young children. It aims to understand how this cancer develops and the best ways to treat it. The trial also includes individuals with DICER1-related conditions. By gathering data from patients, researchers hope to improve treatments and outcomes for these conditions.
The trial's ID number is NCT03382158. This is an observational study, meaning it looks at data without testing new drugs. About 3,400 participants are expected to join the study. It is not regulated by the FDA as a drug or device.
Who can join
Children and adults can join this study. Participants should have known or suspected PPB or related tumors, or DICER1 gene changes. Parents or guardians can give consent for younger participants. The study welcomes healthy volunteers as well. The trial team will confirm who can join.
Conditions
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Age group
All ages
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be grouped based on their type of PPB or related conditions. Those with Type I PPB might have surgery and possibly chemotherapy. Types II and III require surgery and a specific chemotherapy regimen. For Type Ir PPB and DICER1-related conditions, participants will be monitored and followed over time. Treatment decisions are made by the medical team at each location.
Where
This trial is running at 1 location in the United States. It is currently recruiting.